The MoU outlines partnership in several key areas including co-developing and publishing innovative research, delivering expert lectures, organizing educational events such as hackathons and workshops ...

A novel gut-restricted and PHD specific Inhibitor designed and optimized with the support of Insilico’s Chemistry42 commercially-available generative reinforcement learning platform, for Inflammatory ...

Want smarter insights in your inbox? Sign up for our weekly newsletters to get only what matters to enterprise AI, data, and security leaders. Subscribe Now Insilico Medicine, a clinical-stage AI drug ...

CAMBRIDGE, Mass., Nov. 10, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research ...

Though most cancer targets have been considered conventionally “undruggable” (roughly 80 percent, according to Liron Bar-Peled, PhD, an investigator in Mass General’s Krantz Family Center for Cancer ...

Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.

With its unique target discovery platforms, PandaOmics and Chemistry42, AI company Insilico is transforming the world of research and development. Deep learning in biopharma has come of age. After ...

A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits ...

Insilico Medicine, a developer of artificial intelligence technology for drug discovery, has raised $255 million in series C financing. The investment round is the second this year to top $200 million ...

Insilico Medicine, a company that uses artificial intelligence to drive drug discovery, is considering a U.S. initial public offering that could raise about $300 million, according to people familiar ...